Shuttle Pharmaceuticals Announces $3.5 Million Public Offering

Core Viewpoint - Shuttle Pharmaceuticals Holdings, Inc. has announced a public offering of common stock and pre-funded warrants, aiming to raise approximately $3,500,000 for various corporate purposes [1][2]. Group 1: Offering Details - The company will issue 2,238,800 shares of common stock and pre-funded warrants to purchase 4,761,200 shares of common stock [1]. - The offering is expected to close on or about March 9, 2026, pending customary closing conditions [1]. Group 2: Use of Proceeds - Up to $1.5 million of the net proceeds will be allocated for future marketing efforts [2]. - The remaining funds will be used for working capital and general corporate purposes [2]. Group 3: Company Overview - Shuttle Pharmaceuticals owns Molecule.ai, an AI-driven platform for molecular discovery and early-stage drug development [4]. - The platform integrates modern AI techniques with structured scientific workflows to enhance the efficiency of chemical exploration and decision-making in drug development [4].